Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs
This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.
3m Sep 11, 2025
3m
Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence
This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.
3m Sep 10, 2025
3m
Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program
This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.
3m Sep 09, 2025
3m
Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits
This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.
3m Sep 08, 2025
3m
Pharma Pulse: Trump Appeals Tariff Ruling, Sanofi Shares Slide on Trial Miss, and COVID-19 Alters Pneumococcal Mortality
This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.
3m Sep 05, 2025
3m
Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes
This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.
3m Sep 04, 2025
3m
Pharma Pulse: FDA Approves Sanofi’s Wayrilz, OTC Triptans Show Public Health Gains, and Biosimilar Rules Streamlined
This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.
3m Sep 03, 2025
3m
Pharma Pulse: Flu Vaccination Rates Improve, AI Powers RNA Therapeutics, and Statin Intolerance Spurs Self-Medication Risks
This episode of Pharma Pulse covers rising influenza vaccination rates among historically underserved populations, a new Circurna–GATC Health partnership using AI to advance circular RNA therapies, and fresh research showing many statin-intolerant patients are self-medicating despite limited benefits for lowering LDL cholesterol.
3m Sep 02, 2025
3m
Pharma Pulse: Child Vaccines Show Adult Protection, Lilly Pauses Mounjaro Shipments, and FDA Rejects Lytenava Resubmission
This episode of Pharma Pulse covers new evidence that childhood PCV10 vaccines indirectly protect unvaccinated adults, Eli Lilly’s pause in UK Mounjaro shipments following a major price hike, and the FDA’s Complete Response Letter to Outlook Therapeutics’ resubmission for Lytenava in wet AMD.
3m Sep 01, 2025
3m
Pharma Pulse: CDC Director Pushback, Persistent Drug Shortages, and FDA Clears First Generic GLP-1 for Weight Loss
This episode of Pharma Pulse covers Susan Monarez’s rejection of White House efforts to remove her as CDC director, new analysis on how long-lasting drug shortages expose systemic supply chain weaknesses, and the FDA’s approval of the first generic liraglutide for weight management.
3m Aug 29, 2025
3m
Pharma Pulse: ACOG Reaffirms COVID-19 Vaccine in Pregnancy, SGLT2 Real-World Safety Data, and EVERSANA–Waltz Tackle Drug Costs
This episode of Pharma Pulse covers ACOG’s renewed support for COVID-19 vaccination during pregnancy, new real-world evidence confirming the safety of dapagliflozin and empagliflozin for type 2 diabetes, and a partnership between EVERSANA and Waltz Health to improve affordability and patient access.
3m Aug 28, 2025
3m
Pharma Pulse: FDA Boosts Transparency, CDC Appoints mRNA Critic, and Genentech Invests $700M in US Manufacturing
This episode of Pharma Pulse covers the FDA’s new daily adverse event reporting initiative, the CDC’s appointment of an mRNA vaccine critic to lead its COVID-19 immunization workgroup, and Genentech’s $700 million investment in a North Carolina biologics facility.
3m Aug 27, 2025
3m
Pharma Pulse: Novo Nordisk Plant Faces FDA Scrutiny, Off-Label GLP-1 Use Grows, and AbbVie Expands Psychiatry Pipeline
This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant, the rise of off-label GLP-1 prescribing and its equity challenges, and AbbVie’s acquisition of bretisilocin to advance treatments for major depressive disorder.
3m Aug 26, 2025
3m
Pharma Pulse: CVS Caremark Faces $290M Penalty, Small Practices Miss HIPAA Standards, and Pharmacists Underreport Adverse Drug Reactions
This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research revealing why pharmacists underreport adverse drug reactions.
3m Aug 25, 2025
3m
Pharma Pulse: Pharma Tariffs Take Shape, J&J Invests $2 Billion in US Manufacturing, and New EHR Rule Targets Prior Authorization
This episode of Pharma Pulse covers the White House–EU agreement on pharmaceutical tariffs, Johnson & Johnson’s $2 billion expansion of its North Carolina manufacturing site, and a new federal rule requiring e-prescribing and prior authorization tools in certified EHR systems.
3m Aug 22, 2025
3m
Pharma Pulse: Catalent Layoffs, Diabetes Tech Adoption, and Long-Term Heart Risks from Childhood COVID-19
This episode of Pharma Pulse covers Catalent’s decision to cut 350 jobs at its Baltimore gene therapy site, new data showing rising adoption of digital tools for glycemic control in type 1 diabetes, and research linking severe childhood COVID-19 to heightened cardiovascular risk later in life.
3m Aug 21, 2025
3m
Pharma Pulse: Agile Drug Manufacturing Advances, Merck–Skyhawk RNA Deal, and Telehealth Expands Pharmacists’ Role
This episode of Pharma Pulse explores a Battelle–Aprecia partnership with HHS and DARPA to accelerate on-demand drug manufacturing, a multi-billion-dollar Merck KGaA–Skyhawk collaboration to advance RNA therapies in neurology, and how pharmacist-led telehealth is improving diabetes care during emergencies.
3m Aug 20, 2025
3m
Pharma Pulse: Wegovy Wins Accelerated Approval, New Flu Combo Emerges, and Community Pharmacies Expand Access
This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a promising drug combination against resistant influenza strains, and how community pharmacies are strengthening healthcare access in underserved areas.
3m Aug 19, 2025
3m
Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs
This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.
3m Aug 18, 2025
3m
Pharma Pulse: US API Stockpile Plan, Mounjaro Price Hike in UK, and New Data on Vaccine Safety
This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price increase for Mounjaro in the UK, and long-term research confirming the safety of aluminum in childhood vaccines.
3m Aug 15, 2025
3m
Pharma Pulse: AbbVie Boosts Domestic API Manufacturing, Supermarkets Lead in Pharmacy Satisfaction, and GLP-1 Coverage Tightens
This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results showing mail-order and supermarket pharmacies outpacing traditional chains in customer satisfaction, and rising affordability pressures as insurers restrict GLP-1 coverage.
3m Aug 14, 2025
3m
Pharma Pulse: Cardinal Health Expands with Solaris Acquisition, Hospitals Centralize Pharmacy Hubs, and GLP-1 Safety Signals Emerge
This episode of Pharma Pulse dives into Cardinal Health’s acquisition of Solaris Health to strengthen specialty services, how hospital networks are investing in centralized pharmacy hubs to improve efficiency and supply chain resilience, and new research linking GLP-1 drugs to potential optic nerve disorders.
3m Aug 13, 2025
3m
Pharma Pulse: Vinay Prasad Reinstated as FDA CBER Head, New COVID-19 Risk Data, and the Industry’s Response to Rising Costs
This episode of Pharma Pulse covers Vinay Prasad’s return to lead the FDA’s biologics center after a brief resignation, new research on severe COVID-19 risks for childhood cancer survivors, and the strategies pharma companies are adopting to stay competitive amid escalating healthcare costs.
3m Aug 12, 2025
3m
Pharma Pulse: FDA Launches Pre-Check Program, GSK Secures mRNA Settlement, and Pharma Leaders Eye US Investment Boost
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 million mRNA patent settlement with CureVac, and upcoming discussions between industry leaders and policymakers on strengthening US pharmaceutical innovation and supply chains.
4m Aug 11, 2025
4m
Pharma Pulse: Bayer Restructures, Lilly’s Oral GLP-1 Advances, and Court Ruling Shakes Up Obesity Drug Market
This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the way for intensified competition in the high-growth obesity and diabetes treatment market.
4m Aug 08, 2025
4m
Pharma Pulse: Redefining the Pharmacy Aisle
This episode of Pharma Pulse examines how in-store pharmacies are evolving beyond prescriptions to deliver clinical services, nutrition support, and real-time education, bridging care gaps in pharmacy deserts across the United States.
4m Aug 07, 2025
4m
How Recent Executive Orders Impact the Drug Pricing Landscape
In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores how recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies; what life sciences companies should be doing now to proactively prepare for further executive actio...
17m May 30, 2025
17m
Fast-Tracking the Future
In this exclusive PC Podcast interview, Claire Riches, vice president of clinical solutions at Citeline, dives into specific inefficiencies in the current drug approval system that are the biggest obstacles to faster approvals; how the FDA can integrate data sources such as real-world data (RWD) to streamline approvals, while maintaining rigorous safety standards; advancements in data collectio...
12m Apr 25, 2025
12m
Embarking on the CAR-T Journey
In this exclusive PC Podcast interview, Renier Brentjens, MD, PhD, deputy director and chair of medicine at the Roswell Park Comprehensive Cancer Center, discusses how he has seen the field evolve since its inception, and what excites him most about its future; how the Roswell Park expansion helps improve patient access to CAR T-cell therapy; the key safety concerns associated with CAR T-cell t...
19m Mar 31, 2025
19m
Selecting the Right 3PL
In this exclusive PC Podcast interview, Tracy Lopez, North America’s head of customer service and 3PL operations for Dr. Reddy’s Laboratories, explains how the third-party logistics (3PL) process typically operates; key factors manufacturers should take into account when choosing a 3PL, along with the range of services a reliable 3PL should offer; the important lessons learned since the onset o...
9m Feb 28, 2025
9m
A Closer Look Into the Role of Compounding Pharmacies
In this exclusive PC Podcast interview, Donald Prentiss, founder and CEO of Qualthera, explains the role that compounding pharmacies play in the pharmaceutical supply chain; how compounding pharmacies helped bridge the gap for patients in need of their medication (especially during the tirzepatide shortage), while dispelling the notion that commercialized and compounded drugs are competing with...
16m Jan 28, 2025
16m
The Path Forward for Infused Biosimilars in the US
In this exclusive PC Podcast interview, Vibhu Tewary, project director, IQVIA Institute for Human Data Science, discusses highlights of the company’s report surrounding the “Long-term Market Sustainability for Infused Biosimilars in the US: Foundational Analytics on Emerging Risks to Sustainability"; the process that constructing and piecing together a report of this magnitude entails, along wi...
12m Dec 18, 2024
12m
Nov. 27 is Here: What Does That Mean for DSCSA?
In this episode of The PC Podcast, Nicholas Saraceno, Pharma Commerce’s editor, explains the history behind the Drug Supply Chain Security Act (DSCSA); the significance of Nov. 27; the latest DSCSA exemptions and what that means for trading partners; and how this piece of legislation and AI are able to intertwine.
7m Nov 27, 2024
7m
The Impact of RFID: Enhancing Medication Management
In this exclusive PC Podcast interview, Rob Sobie, chief product officer of Intelliguard, a provider of hospital medication management and data intelligence solutions, discusses the key challenges that hospitals are currently facing; why he believes that the drug supply chain is failing; successes surrounding the implementation of RFID technology; and a high-level overview of the Drug Supply Ch...
11m Oct 25, 2024
11m
Incorporating AI into Commercialization Plans
In this exclusive PC Podcast interview, Steve Silvestro, president of OptimizeRx, a digital communications platform, details: the benefits to integrating direct-to-consumer (DTC) and healthcare provider (HCP) marketing strategies with technology, especially for patients and providers; the application of artificial intelligence (AI) toward the pharma marketing stage of commercialization; ways th...
14m Sep 30, 2024
14m
The Capabilities of a 3PL Provider
In this exclusive PC Podcast interview, Chris Williams, International Managing Director of Alloga Europe and ICS, discusses what’s needed to support advanced therapy medicinal products from a temperature standpoint; the current state of third-party logistics (3PLs) in Europe and what areas need to improve; how expectations of pharma companies have changed in terms of what they expect a 3PL part...
9m Aug 26, 2024
9m
Addressing the Drug Shortage Crisis
In this exclusive PC Podcast interview, Peter Ax, founder and CEO of UpScriptHealth, a direct-to-consumer telehealth company, describes why he believes ongoing and active drug shortages are the highest they’ve been since ASHP began tracking this in 2001; the current landscape of shortages in general; how drug shortages directly affect patients; and what is needed to alleviate these issues surro...
12m Jul 31, 2024
12m
Navigating Market Access Hurdles
In this exclusive PC Podcast interview, Mark Bouck, chairman and CEO of PharmAlliance, a pharmaceutical and life sciences services platform, dives into how PharmAlliance’s acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS) helps expand global reach; the platform’s biggest goal to when it comes to CHEORS and market access services; how CHEORS helps navigate cost-effect...
5m Jun 21, 2024
5m
Overcoming Supply Chain Challenges
In this exclusive PC Podcast interview, Chip Davis, president and CEO of the Healthcare Distribution Alliance (HDA), a national organization that represents primary pharmaceutical distributors, discusses the benefits of the Distribution Management Conference, and the value it provides for the industry; a three-year check-in since his last chat with Pharmaceutical Commerce, including a look at h...
15m May 17, 2024
15m
Mitigating Drug Shortages
In this exclusive PC Podcast interview, Allen Jacques, a life sciences industry thought leader at Kinaxis, dives into what he sees as limitations of current government efforts when it comes to boosting domestic production of essential medicines, and why they aren’t sufficient; how and why drug shortages occur; the challenges that generic drug manufacturers are facing today; and why more resilie...
11m Apr 12, 2024
11m
A Further Examination of Pharmacy Benefit Managers
In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores the implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system; the role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involv...
15m Mar 29, 2024
15m
A First-Hand Account of 3PLs
In this exclusive PC Podcast interview, Rob Besse, Archbow Consulting’s VP of distribution services, shares a general overview of how the 3PL process works, using his 20-plus of pharma supply chain experience as added insight; the factors that manufacturers should consider when selecting a 3PL, along with the array of services that a quality 3PL should provide; valuable lessons he believes 3PLs...
16m Feb 29, 2024
16m
Complying With the DSCSA
In this exclusive PC Podcast interview, Dave DeJean, Systech’s VP of global strategic accounts, dives into the valuable lessons he’s learned along the way, given his three and half decades of experience at Systech; an overview of the Drug Supply Chain Security Act (DSCSA), including its three main pillars; how he would interpret this “Stabilization Period” that the FDA provided this past summer...
16m Jan 24, 2024
16m
Treating Psoriasis While Providing Patient Support
In this PC Podcast interview that originally aired for Pharmaceutical Executive, Camille Lee, UCB’s SVP and US head of immunology, dives into the history behind UCB's work in psoriasis; the significance behind UCB announcing the commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; how Bimze...
12m Dec 22, 2023
12m
A Year in Review
In this PC Podcast episode, Editor Nicholas Saraceno reviews the past year by providing a look at five articles that made a splash.
16m Nov 29, 2023
16m
Implementing Sustainable Business Practices
In this exclusive PC Podcast interview—sponsored by Alltrista—Raphael Chin Fo Sieeuw, DHL’s VP of life sciences and healthcare, Americas, uncovers how his plethora of experience successfully prepared him to perform the required duties in his current position; the latest trends that are helping to reshape and impact the pharma supply chain; what can be done to combat 300 million tons of plastic ...
14m Oct 30, 2023
14m
Supply Chain Safeguards
In this exclusive PC Podcast interview, Jason Cook, Cardinal Health’s director of operations, explores the importance of having a comprehensive contingency plan, especially before weather-related disruptions begin; what needs to be done by pharma companies post-disaster in order to not only create a stronger strategy for next time, but to also have customers feel seen and included throughout th...
15m Sep 29, 2023
15m
ESG Evolution
In this exclusive PC Podcast interview, Susanne Katus, SVP, market leader, corporate secretary at Datamaran, a platform that monitors and analyzes risk factors, dives into the growing number of environmental, social, and governance (ESG) regulations impacting these aforementioned businesses; where the responsibility lies for them in terms of ESG compliance; what can be done in order for these c...
10m Aug 25, 2023
10m
The DSCSA Overview
Gregg Gorniak, senior director of manufacturer operations & data services at AmerisourceBergen, provides a history and overview of the Drug Supply Chain Security Act (DSCSA), including how prepared the pharma supply chain is in successfully implementing its requirements.
22m Jun 23, 2023
22m
Protecting Patient Access to Medication in the Midst of Crisis
Tom Cotter, executive director of Healthcare Ready, a non-profit organization, dives into ways to facilitate solutions in the face of a disaster, including how to protect patient access to medication during these times of crisis.
20m Apr 21, 2023
20m